Top 10 Medical Aesthetics Companies

Why Is the Medical Aesthetics Market Expanding?

The Global Medical Aesthetics Market is seeing significant structural growth, rising from USD 23.36 billion in 2025 to an estimated USD 54.91 billion by 2035, at a CAGR of 8.92% during the forecast period of 2025-2035.

According to Market Research Future (MRFR), three converging forces are driving the market acceleration – the rapidly aging global population that is fuelling demand for anti-aging and skin-rejuvenation solutions, the democratisation of minimally invasive procedures through improved safety profiles and reduced recovery time, and the impact of digital platforms in normalising aesthetic treatments across younger demographics globally.

The facial aesthetics section dominated the largest application segment, holding a revenue share of 57% in 2025. The growth of this segment is mainly driven by botulinum toxin injections, hyaluronic acid dermal fillers, and non-invasive facial rejuvenation technologies. The fastest-growing application segment is body contouring, which is driven by increasing demand for non-surgical fat reduction and skin tightening procedures.

This is partly driven by the rapid adoption of GLP-1 weight loss drugs, which has created a new pool of patients who require body contouring treatments after losing weight. Injectables are the leading product type, with 64% of revenue share, and non-invasive treatments make up 68% of procedure volume. In terms of revenue share, North America is the leading segment, accounting for more than 50.35% of the worldwide revenue in 2024, which is around USD 10.8 billion, owing to high consumer spending, advanced clinical infrastructure, and strong digital health adoption.

The WHO estimates that the world population of 60+ years will hit 2.1 billion by 2050, which will continue to support long-term structural demand for anti-aging aesthetic procedures. In 2024, Hugel’s Letybo (letibotulinumtoxinA) was approved by the FDA, adding to the premium neuromodulator market and fueling competition between Botox Cosmetic and Dysport in U.S. aesthetic operations.

Why Are These Companies Leading the Market?

MRFR identifies four structural factors separating category leaders in the Medical Aesthetics Market: injectable portfolio depth and physician brand equity, technology differentiation through energy-based device innovation, global regulatory approval coverage enabling multi-market commercialisation, and disciplined M&A strategy to access new treatment modalities and geographic distribution.

Injectable portfolio depth and physician brand equity define the revenue leaders. Allergan Aesthetics has built a multi-decade prescriber relationship network through Botox Cosmetic — the world's most recognised neuromodulator brand — and the Juvederm HA filler collection, creating a high-switching-cost ecosystem within dermatology and plastic surgery practices.

Galderma's technology differentiation is exemplified by Relfydess™ (RelabotulinumtoxinA), a liquid-formulation neuromodulator requiring no refrigerated reconstitution. Geographic regulatory coverage defines Ipsen's competitive moat, with Dysport holding approvals across 80+ markets globally. M&A strategy drives Crown Laboratories, which acquired Revance Therapeutics in 2025 to build an independent premium injectable aesthetics platform centred on DAXXIFY.

Top 10 Global Medical Aesthetics Companies — MRFR Rankings (2026)

MRFR has identified and profiled the following leading medical aesthetics companies globally, evaluated on the basis of revenue performance, market capitalisation, geographic presence, product breadth, innovation strategy, and physician client base.

Rankings based on MRFR analysis. Revenue figures sourced from official company filings and investor relations disclosures where publicly available. Private-company and subsidiary figures are analyst estimates. CC = constant currency.

Detailed Company Profiles

1. Allergan Aesthetics (AbbVie Inc.) | NYSE: ABBV | Irvine, California, USA

Allergan Aesthetics, an AbbVie Inc. company, is the global market leader in medical aesthetic injectables, offering the world’s most recognised neuromodulator brand, Botox Cosmetic (onabotulinumtoxinA), the Juvederm collection of hyaluronic acid dermal fillers, SkinVive by Juvederm intradermal biorevitaliser and the CoolSculpting cryolipolysis body-contouring platform.

In FY2024, total aesthetics portfolio revenue was USD 5,176 million, including USD 2,720 million for Botox Cosmetic and USD 1,177 million for Juvederm (per AbbVie official Q4 2024 and full-year earnings press release, January 31, 2025). The injectable portfolio of the division is distributed through a network of approximately 50,000 trained aesthetic practitioners in more than 100 countries.

2. Galderma Group AG | SIX: GALD | Zug, Switzerland

Galderma Group AG is the world’s largest pure-play dermatology company, with three segments: Injectable Aesthetics (Restylane fillers, Sculptra biostimulator, Dysport and Azzalure neuromodulators and Relfydess), Dermatological Skincare (Cétaphil and Alastin) and Therapeutic Dermatology (Nemluvio). Galderma’s overall net sales in FY2025 were USD 5,207 million, also exceeding USD 5 billion for the first time and reflecting a year-on-year growth of 17.7% at constant currency (Galderma official FY2025 results, March 5, 2026). Injectable Aesthetics net sales of $2,572 million (+11.5% CC). Relfydess™ Approved in 23 International Markets By Year-End 2025 BLA Resubmission Accepted by FDA on February 2, 2026

3. Merz Aesthetics | Private | Raleigh, USA / Frankfurt, Germany

Merz Aesthetics is the aesthetic medicine division of Merz Pharmaceuticals GmbH, operating a comprehensive multi-modal portfolio including Xeomin®/Bocouture® (incobotulinumtoxinA) neuromodulators, the Belotero® collection of HA dermal fillers, Radiesse® calcium hydroxylapatite biostimulator, the Ultherapy® microfocused ultrasound skin-tightening platform, and the Neocutis skincare brand. The company distributes its products through aesthetic practitioners in 70+ countries, with commercial concentration in North America, Germany, France, and Latin America.

4. Ipsen S.A. | Euronext Paris: IPN | Paris, France

Ipsen S.A. is a global specialty pharmaceutical company whose aesthetic portfolio centres on Dysport® (abobotulinumtoxinA), one of the three major commercially approved botulinum toxin products globally. Ipsen reported total sales of EUR 3,400.6 million in FY2024 (EUR 3,574.5 million including other revenues of EUR 173.9 million), representing 8.7% reported growth year-over-year (per Ipsen official FY2024 full-year results, February 13, 2025). 

5. Hugel Inc. | KOSDAQ: 145020 | Chuncheon, South Korea

Hugel Inc. is South Korea's largest medical aesthetics company, specialising in botulinum toxin products and hyaluronic acid dermal fillers. The company's flagship product Letybo® (letibotulinumtoxinA-ltbc) is the first Korean-origin botulinum toxin to receive US FDA approval, achieved in 2024, enabling commercial entry into the world's largest neuromodulator market. Hugel distributes its products across 50+ countries with particular commercial strength in Asia-Pacific, Europe, and Latin America.

6. Bausch Health Companies / Solta Medical | NYSE: BHC | Laval, Canada

Bausch Health's global aesthetics business, Solta Medical, is a market-leading energy-based medical device company operating a portfolio of radiofrequency, laser, and ultrasound platforms including Thermage® FLX, Fraxel®, Clear + Brilliant®, and VASER®. Solta Medical distributes through a direct and partner network in 100+ countries, with China representing one of its highest-growth markets. In December 2025, Solta acquired the Wuhan Shibo Zhenmei Technology distribution subsidiary, converting a decade-long distribution partner into a wholly owned subsidiary for direct commercial control of Thermage FLX sales across China.

7. Medytox Inc. | KOSDAQ: 086900 | Seoul, South Korea

Medytox Inc. is a South Korean biopharmaceutical company specialising in botulinum toxin products and hyaluronic acid dermal fillers for therapeutic and aesthetic applications. The company's primary aesthetic products include Meditoxin®/Neuronox® botulinum toxin across multiple international markets, alongside a growing range of HA dermal filler products. Medytox serves aesthetic practitioners in 50+ countries, with commercial concentration in Asia-Pacific, the Middle East, and Latin America, and operates an active R&D programme targeting next-generation toxin formulations.

8. InMode Ltd. | NASDAQ: INMD | Yokneam, Israel

InMode Ltd. is a global medical technology company specialising in minimally invasive and non-invasive energy-based aesthetic platforms. The company reported full-year 2025 revenue of USD 370.5 million, a 6% year-on-year decrease compared to USD 394.8 million in FY2024 (per official InMode Q4 FY2025 press release, February 10, 2026). International (non-US) sales represented approximately 46% of total FY2025 revenue, reflecting continued global expansion even as US market conditions remained challenging. InMode's flagship platforms include Morpheus8®, BodyTite®, Optimas®, Evoke®, and AccuTite®, supported by 37 FDA clearances across its portfolio.

9. Revance Therapeutics (Crown Laboratories) | Private (post-acquisition) | Nashville, Tennessee, USA

Revance Therapeutics was acquired by Crown Laboratories in Q1 2025 following a tender offer process that began with an August 12, 2024 announcement at a total enterprise value of USD 924 million (USD 6.66 per share). The deal was subsequently renegotiated — an Amended and Restated Merger Agreement dated December 7, 2024 reduced the price to USD 3.10 per share, and a further amendment in January 2025 set the final price at USD 3.65 per share, expected to close by February 6, 2025 (per Crown and Revance official SEC filings).

Revance commercialises DAXXIFY® (daxibotulinumtoxinA-lanm), differentiated by a median duration of 24 weeks per treatment, and the RHA® Collection of resilient hyaluronic acid fillers. Following Crown's acquisition, the combined entity is expanding DAXXIFY commercial targeting and initiating international regulatory submissions.

10. Lumenis Aesthetics | Private (BPEA ownership) | Yokneam, Israel

BPEA explicitly retained full ownership of Lumenis Aesthetics and Ophthalmology at the time of that transaction (per Boston Scientific and BPEA official joint press release, March 3, 2021). Lumenis Aesthetics has continued to operate as an independent aesthetics technology company under BPEA private equity ownership, with no Boston Scientific ownership stake in the aesthetics business.

M&A Activity Tracker (2022–2026)

The Medical Aesthetics Market has experienced sustained consolidation as leading pharmaceutical and medtech companies pursue inorganic growth to expand injectable portfolios, enter energy-based device adjacencies, and acquire distribution infrastructure in high-growth markets. Key corrections from the original document are noted inline.

Key Trend: MRFR analysis identifies injectable portfolio consolidation and energy-based device platform acquisition as the dominant M&A themes across 2022–2026, with acquirers prioritising neuromodulator and HA filler assets that expand prescriber reach alongside laser and RF device platforms that provide capital equipment revenue complementary to consumable injectable sales.

R&D Investment & Innovation Signals

R&D investment across the Medical Aesthetics Market has accelerated in 2025–2026 as vendors race to develop next-generation neuromodulators with extended duration, biostimulator fillers with regenerative tissue effects, and AI-integrated energy-based devices with personalised treatment protocols. Market Research Future tracks the following verified 2025–2026 R&D and innovation programmes from official company sources:

• Galderma advanced Relfydess™ (RelabotulinumtoxinA) across international markets in 2025, supported by Phase IV nine-month data demonstrating durable patient satisfaction and workflow efficiency advantages over conventional reconstituted toxins. Relfydess received approval in 23 international markets by year-end 2025, with US FDA BLA resubmission accepted February 2, 2026, for glabellar lines and crow's feet indications.

• Allergan Aesthetics presented Phase 3 clinical study results for a first-in-class botulinum neurotoxin serotype E (trenibotulinumtoxinE) at the ASDS Annual Meeting in November 2025, introducing a novel toxin serotype with a distinct mechanism of action that may deliver differentiated onset kinetics and duration profiles compared to established serotype A neuromodulators.

• Ipsen advanced IPN10200, its next-generation botulinum toxin candidate engineered for extended duration and improved dose-response predictability, into Phase III clinical trials in 2025 — the most significant aesthetics pipeline investment in Ipsen's history and a direct competitive challenge to DAXXIFY in the long-duration premium neuromodulator category.

• Hugel established US physician training infrastructure for Letybo® in 2025 following FDA approval, investing in comparative real-world outcomes studies to generate clinical evidence against established neuromodulator brands and accelerate practitioner conversion across North American aesthetic practices.

Industry Signal: MRFR identifies the convergence of next-generation long-duration neuromodulators (DAXXIFY, IPN10200, BoNT-E), biostimulator filler innovation, and AI-integrated device platforms as the overarching innovation direction reshaping competitive differentiation in the Medical Aesthetics Market, with vendors successfully combining evidence-based clinical performance with digital patient engagement and practice management tools positioned to capture durable prescriber loyalty.